Dallas, TX â?? January 4, 2017 â?? Puration, Inc. (PURA) today announced its support for the anticipated acquisition of Spanish Peaks ScrumpDelicacies by ML Capital Group (MLCG).
PURA recently published a confirmation and update of its $1 million collaboration agreement with Spanish Peaks ScrumpDelicacies. Earlier this year, PURA and Spanish Peaks entered into a collaboration agreement to produce a line of cannabis Infused beverages. In conjunction with the agreement, Spanish Peaks conducted a cannabis beverage naming contest and announced the contest winners on October 21, 2016.
Earlier today, MLCG announced letter of intent to acquire Spanish Peaks Scrumpdelicacies and enter the $7 billion in 2016 revenue cannabis sector. MLCG a diversified holding company expanding its presence in the luxury and specialty travel markets with the pending acquisition of Spanish Peaks ScrumpDelicacies. MLGC has an established presence in the luxury travel market, highlighted by its flagship operation, Platinum Tours of Maui. MLGC will leverage the Spanish Peaks ScrumpDelicacies acquisition to launch a new, specialty tourism sector focused exclusively on cannabis-related travel experiences.
â??Spanish Peaks becoming a key asset of a micro-cap public company is an exciting step in the development of the collaboration agreement between Puration and Spanish Peaks,â? said Brian Shibley, CEO of Puration. â??We are enthusiastic about the prospects of the MLCG and Spanish Peaks deal coming to fruition. We have welcomed the opportunity to be included in the discussions between MLCG and Spanish Peaks, and we are optimistic that the deal between MLCG and Spanish Peaks is good for the collaboration agreement between Puration and Spanish Peaks and in turn, good for the Puration shareholders.â?
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that Alkame will achieve significant sales, the failure to meet schedule or performance requirements of the Company’s contracts, the Company’s liquidity position, the Company’s ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.